Fair Value Measurements - Additional Information (Details) $ in Thousands			12 Months Ended
	Jul. 16, 2021 shares	May 03, 2019 USD ($)	Dec. 31, 2021 USD ($) shares	Dec. 31, 2020 USD ($) shares	Dec. 31, 2019 USD ($)	Dec. 31, 2017 USD ($)	Jun. 01, 2021 USD ($)
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Common stock, shares outstanding (in shares) | shares			314,573,225	275,285,582
Common stock shares value subject to transfer restrictions			$ 90,217	$ 0
Current portion of contingent consideration			7,934	398
Re-measurement of Fair Value			9,198	0	$ (736)
Settlement of contingent consideration				0	10,354
(Loss) gain on derivative liabilities			$ (300)	$ 6,600	(36,792)
Debt discount					7,000
2019 Warrants
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Loss on derivative liability		$ 4,300
Early Conditional Loan
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Loss on derivative liability					$ 1,800
Revenue Multiple
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Derivative liability, measurement input				1
Revenue Multiple | Minimum
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Derivative liability, measurement input					0.55
Revenue Multiple | Maximum
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Derivative liability, measurement input					1
Discount for lack of marketability
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Discount rate for lack of marketability			0.140
Scilex Notes | Risk Adjusted Net Sales Forecast
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Derivative liability, measurement input			0.062	0.07	0.08
Scilex Notes | Effective Debt Yield
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Derivative liability, measurement input			0.150	0.15	0.197
ACEA Therapeutics, Inc
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Contingent consideration							$ 122,100
(Gain) related to the settlement of acquisition consideration payable			$ 9,200
ACEA Therapeutics, Inc | Effective Debt Yield
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Derivative liability, measurement input			1.50				1.44
ACEA Therapeutics, Inc | Put Option
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Current portion of contingent consideration			$ 7,500				$ 8,900
TNK Therapeutics | Virttu Biologics Limited
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
(Gain) related to the settlement of acquisition consideration payable						$ (10,400)
Class A Common Stock | Celularity
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Common stock, shares outstanding (in shares) | shares			20,422,124
Common stock received | shares	19,922,124		19,922,124
Common stock shares value subject to transfer restrictions			$ 87,700
Acquisition Consideration
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Re-measurement of Fair Value					$ 700